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Abstract
Spin-labeled podophyllotoxins have elicited widespread interest due to their far superior antitumor
activity compared to podophyllotoxin. To extend our prior studies in this research area, we
synthesized a new generation of spin-labeled podophyllotoxin analogs via isocyanide
multicomponent reactions and evaluated their cytotoxicity against four human cancer cell lines
(A-549, DU-145, KB and KBvin). Most of the compounds exhibited potent cytotoxic activity
against all four cell lines, notably against the drug resistant KBvin cancer cell line. Among the
new analogs, compounds 12e (IC50: 0.60–0.75 µM) and 12h (IC50: 1.12–2.03 µM) showed
superior potency to etoposide (IC50: 2.03 – >20 µM), a clinically available anticancer drug. With a
concise efficient synthesis and potent cytotoxic profiles, compounds 12e and 12h merit further
development as a new generation of epipodophyllotoxin-derived antitumor clinical trial
candidates.
Keywords
Podophyllotoxin; C-4 position; Spin labeled; Isocyanide multicomponent reactions; Cytotoxic
activity
© 2014 Elsevier Masson SAS. All rights reserved.
*To whom correspondence should be addressed. Tel.: (919) 962-0066. Fax: (919) 966-3893. khlee@email.unc.edu (K.H. Lee);
yqliu@lzu.edu.cn (Y.Q. Liu).
†These authors contributed equally to this work.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Eur J Med Chem. Author manuscript; available in PMC 2015 March 21.
Published in final edited form as:














In recent years, multi-component reactions (MCRs) have played a central role in the
development of modern synthetic methodology for drug discovery research. The
applications in this field are quite broad extending from initial lead structure identification to
generation of large libraries of analogs. Combined with the power of in silico screens, this
methodology is an efficient tool for the modern medicinal chemist. MCRs that involve
isocyanides (IMCRs) are by far the most versatile reactions in terms of scaffolds and
number of accessible compounds [1–3]. Many advantages over conventional linear-type
syntheses make IMCRs very popular in the medicinal chemistry community: superior atom
economy, low costs, high variability, high bond forming efficiency, and simple
environmentally benign procedures. From this standpoint, design- or logic-based discovery
utilizing IMCR could be advantageous. Consequently, the application of IMCR offers an
efficient synthetic route to construct diverse podophyllotoxin-based scaffolds for drug
discovery.
Podophyllotoxin (1, PPT), a naturally occurring lignin, exerts cytotoxic activity by
inhibition of microtubule assembly [4,5]. Its two semisynthetic glucoconjugates, etoposide
(2) and teniposide (3), are novel DNA topoisomerase II inhibitors marketed in several
countries [6,7]. Some non-sugar substituted analogues, particularly N-linked congeners,
exhibit superior pharmacological properties to etoposide, and consequently, several newer-
generation clinical candidates, including NPF (4) [8], GL-331 (5) [9], and TOP-53 (6) [10],
have emerged through C-4 modification as alternatives to overcome the drawbacks of
etoposide. In addition, another important area of podophyllotoxin research involves the
synthesis and design of novel spin-labeled PPT derivatives by our group over the past
decades [11–20], providing potential drugs with beneficial therapeutic profiles, e.g.,
improved activity or higher solubility, better pharmacokinetics, or reduced side effects.
Among the highlights of this research, first generation spin-labeled podophyllotoxin
derivatives represented by GP-7 (7, Fig. 1) and GP-11 (8) are the most important, because of
their high potency, low toxicity, broad antitumor spectra, and better formulation/usage
characteristics. After them, second generation spin-labeled amino acid-linked derivatives
were investigated [21–23] and some of them showed superior or comparable activity against
particular cancer types compared to 2, while their drug-resistance profiles were significantly
different from those of 1. Besides, some compounds were effective at a lower dose than
etoposide in drug-sensitive and drug-resistant xenograft models, demonstrating their
potential as drug candidates for anticancer chemotherapy.
Although numerous syntheses and structure modifications of podophyllotoxins have been
performed, most changes at the C-4 position of PPT have been relatively simple, such as
incorporation of 4β-substituted ethers, esters, and N-linked congeners [24–30]. Modification
of this position with diverse structures via MCRs has attracted less interest. Furthermore,
typical synthetic strategies often suffer from one or more limitations, including long reaction
times, tedious work-up procedures, or lack of general applicability and stereoselectivity,
which makes them unsuitable not only for large-scale synthesis of this class of biologically
active molecules but also for synthesis of screening libraries for drug discovery or for
industrial production. To enrich the limited set of podophyllotoxin derivatives typically
employed in drug discovery, we recently described an efficient synthesis of 4β-
isocyanopodophyllotoxins by dehydration of the corresponding formamide under both
ultrasonic and classical conditions [31]. Based on the success of the above reaction, we
subsequently developed a practical IMCR to synthesize podophyllotoxin derivatives. Herein,
we first report the use of Ugi (Ugi-4CR) and Passirini (P-3CR) reactions as a versatile
approach towards the synthesis of third generation novel spin-labeled podophyllotoxin
series. To our knowledge, these examples are also the first where a nitroxide participated in
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such IMCRs. Some of the obtained compounds have been screened for cytotoxic activity
and exhibited considerable, yet selective potency against certain cancer cell types. With a
concise efficient synthesis and potent cytotoxic profiles, compounds 12e, 12h and 13c merit
further development as new generation spin-labeled epipodophyllotoxin-derived antitumor
clinical trial candidates.
2. Results and discussion
2.1.Chemistry
Our synthetic routes are outlined in Schemes 1 and 2. Briefly, the precursor 4β-
aminoepipodophyllotoxin (9) was prepared stereoselectively from 1 through azidation and
catalytic hydrogenation according to a previously reported method [32]. Next, compound 9
was converted to 4β-formamido-4-deoxypodophyllotoxin (10) in excellent yield by reaction
with ethyl formate under both classical and ultrasonic conditions. Subsequently, dehydration
of 10 with p-toluenesulfonyl chloride in pyridine furnished the key intermediate 4β-
isocyanopodophyllotoxin (11) in good yield [31]. Finally, two novel series of target
compounds 12a–j and 13a–l were obtained via Passerini and Ugi reactions in moderate to
good yields, respectively. The Passirini reaction (Scheme 1) involved three components:
aldehyde/ketone, stable nitroxyl radical acid, and 4β-isocyanopodophyllotoxin (11). The
reaction gave a series of novel spin-labeled epipodophyllotoxin derivatives with an α-
acyloxy carboxamide group.
The Ugi reaction (Scheme 2) involved four components: aldehyde/ketone, amine, stable
nitroxide radical acid, 4β-isocyanopodophyllotoxin (11). This reaction mixture gave another
series of spin-labeled derivatives with a α-acylamino carboxamide group. All newly
synthesized compounds were purified by column chromatography and their structures were
characterized by HRMS, ESR and IR spectroscopic analysis.
2.2. Cytotoxicity
Target compounds 12a–j and 13a–l were evaluated for in vitro cytotoxicity against four
human tumor cell lines, A549 (non-small cell lung cancer), DU145 (prostate cancer cell
line), KB (nasopharyngeal carcinoma), and KBvin [multi-drug resistant (MDR) KB subline
selected using vincristine], using a sulforhodamine B colorimetric (SRB) assay with
triplicate experiments [33]. Compound 2 was included as a positive control and the results
are summarized in Table 1.
As illustrated in Table 1, except for compounds 12b and 13d–l, most of the tested
compounds exhibited moderate to potent cytotoxicity against the four human tumor cell
lines. Remarkably, these compounds retained similar levels of cytotoxicity against the drug
resistant KBvin and KB tumor cell lines, while 2 lost its activity completely (IC50 > 20 vs
3.88 µM). This result agrees with our prior observation that C4-amino substitution of
epipodophyllotoxin is good for overcoming drug-resistance [34–36]. Among the tested
compounds, compounds 12e and 12h showed superior activity with IC50 values of 0.60–
1.46 µM compared to those of 2 (IC50 2.03–3.88 µM) against A549, DU-145, and KB tumor
cell lines.
Compounds 12e and 12h have a methoxy and methylenedioxy substituted phenyl ring,
respectively, in their α-acyloxy carboxamide side chain, while 12b has an unsubstituted
phenyl ring in the same position. This minor structural difference is notable as 12b was
completely inactive against all four tumor cell lines. Two additional compounds with an
aromatic ring in the α-acyloxy carboxamide side chain, 12g with a furan ring and 12f with a
benzyl group, displayed moderate potency (IC50 6.53–7.71 µM). Therefore, future structural
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modifications will focus on introducing various substituted aromatic rings in the α-acyloxy
carboxamide side chain.
Among compounds 12a, 12c, and 12d with alkyl groups in the α-acyloxy carboxamide side
chain, cytotoxic activity generally decreased as the size of the substituents increased. For
example, against the A549 cancer cell, the IC50 value of 12a (two methyl groups) was 2.38
µM, while the IC50 values of 12c (H and propyl group) and 12d (cyclohexane) were 8.86
and 9.52 µM, respectively, indicating that the size of substituent groups might critical.
Compounds 12c, 12j and 12i differ only in the identity of the nitroxide. The three
compounds exhibited similar potency; thus, ring size and degree of unsaturation had no
effect, which was consistent with the literature [19].
Surprisingly, in the α-acylamino carboxamide series, only three (13a–c) compounds
displayed cytotoxicity, albeit only moderate, against the four human tumor cell lines. It is
not clear why most α-acylamino carboxamide analogs were inactive, while corresponding α-
acyloxy carboxamide derivatives (e.g., 13h vs 12e, 13d vs 12a) were active. However, a
general relationship between substituent size and activity appears to be present and merits
further investigation.
3. Conclusion
In summary, efficient isocyanide multicomponent reactions have been developed to prepare
newer-generation structurally diverse spin-labeled derivatives of epipodophyllotoxin. This
approach is a valuable tool in design and synthesis of new podophyllotoxin analogs with
advantages of simplicity, atom-economy, and good yields. The cytotoxic results showed that
most of the new compounds exhibited moderate to potent cytotoxic activity against A-549,
DU-145, KB and KBvin, and overcame acquired drug resistance in the latter cell line.
Among them, compounds 12e and 12h were the most promising derivatives and were
selected as lead molecules for further development. Additional systematic structural
modifications will be carried out to further clarify these initial interesting findings. Future
applications could also involve development of versatile biologically significant
podophyllotoxin fragments into MCR products, chemical libraries created via MCRs, and
heterocycles built from isocyanides.
4. Experimental section
4.1. Chemistry
Melting points were determined on a Kofler apparatus and are uncorrected. IR spectra were
measured on a Nicolet 380 FT-IR spectrometer on neat samples placed between KBr plates.
Mass spectra were recorded on a Bruker Daltonics APEXII49e spectrometer with ESI
ionization source. Electron spin resonance (ESR) spectra were obtained on a Bruker A300
X-band EPR spectrometer. 1H and 13C NMR spectra were recorded at 400 MHz and 100
MHz on a BrukerAM-400 spectrometer using TMS as reference (Bruker Company, USA).
Podophyllotoxin (1) was isolated from the Chinese medicinal herb Juniperus sabina
Linnaeus, and served as the starting material for preparation of all new derivatives. The
precursor 4β-aminoepipodophyllotoxin (9) was synthesized by our previously reported
procedures, and its structure was confirmed by direct comparison with an authentic sample
and previously reported spectroscopic data [32].
4.2. Synthesis of key intermediate 4β-isocyanopodophyllotoxin (11)
The key intermediate 4β-isocyanopodophyllotoxin (11) used for the experiments was
prepared by our previous procedure [31].Yield 67%; m.p. 115–117 °C; IR (KBr, cm−1) 2130
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(NC), 1779 (lactone), 1588, 1506 and 1485 (aromatic C=C), 930 (OCH2O). 1H NMR (400
MHz, CDCl3) δ 6.91 (s, 1H, H-5), 6.56 (s, 1H, H-8), 6.26 (s, 2H, H-2',6'), 6.03 (dd, J = 7.9,
1.1 Hz, 2H, OCH2O), 4.99 (d, J = 4.4 Hz, 1H, H-4), 4.68 (d, J = 5.1 Hz, 1H, H-1), 4.39 (m,
2H, H-11), 3.81 (s, 3H, 4'-OCH3), 3.75 (s, 6H, 3',5'-OCH3), 3.20 (q, 1H, H-2), 2.96 (m, 1H,
H-3). 13C NMR: (CDC13, 400 MHz) δ: 173.01, 160.01, 152.78, 149.27, 147.95, 137.64,
134.32, 131.59, 125.13, 110.53, 108.71, 108.33, 101.95, 67.69, 60.73, 56.35, 53.53, 43.53,
41.37, 35.24. MS (EI) m/z: 424 (M+1); HRMS (m/z) calcd for C23H21NO7: 441.1656 [M
+NH4]+, Found: 441.1652 [M+NH4]+.
4.3. General procedure for synthesis of 20a–j
To a solution of aldehyde/ketone (0.13 mmol) in MeOH (10 mL) was added stable nitroxide
radical acid (0.13 mmol) and 4β-isocyanopodophyllotoxin (11) (0.10 mmol) at room
temperature. The reaction mixture was subsequently heated at reflux for 5 h. Upon
completion of the reaction (TLC monitoring), the mixture was cooled to room temperature
and solvent was evaporated. The residue was purified by chromatography on silica gel using
EtOAc/petroleum ether as eluant to give 12a–j.
4.3.1. Compound 12a—Yield 36%; m.p: 83–85 °C; IR (KBr) cm−1: 3431 (N-H), 1776,
1717 (C=O), 1589, 1506, 1484, 1465 (Ar), 1383 (N-O), 931 (OCH2O); ESR (1×10−5 mol/L
in EtOH): go=2.0057, AN=14.9×10−4, ΔHo=2.66×10−4; MS (EI) (m/z): 667 [M+2H]+;
HRMS (ESI) (m/z) for C35H41N2O11 [M+Na]+: calc. 688.2710, found 688.2723.
4.3.2. Compound 12b—Yield 52%; m.p: 138–139 °C; IR (KBr) cm−1: 3433 (N-H),
1778, 1723 (C=O), 1589, 1504, 1485 (Ar), 1385 (N-O), 935 (OCH2O); ESR (1×10−5 mol/L
in EtOH): go=2.0057, AN=14.8×10−4, ΔHo=2.61×10−4; MS (EI) (m/z): 736 [M+Na]+;
HRMS (ESI) (m/z) for C39H41N2O11 [M+Na]+: calc. 736.2710, found 736.2752.
4.3.3. Compound 12c—Yield 79%; m.p: 113–115 °C; IR (KBr) cm−1: 3437 (N-H), 1778,
1720 (C=O), 1588, 1506, 1484, 1466 (Ar), 1383 (N-O), 932 (OCH2O); ESR (1×10−5 mol/L
in EtOH): go=2.0058, AN=14.7×10−4, ΔHo=2.65×10−4; MS (EI) (m/z): 680 [M+H]+; HRMS
(ESI) (m/z) for C36H43N2O11 [M+H]+: calc. 680.2867, found 680.2864.
4.3.4. Compound 12d—Yield 66%; m.p: 119–121 °C; IR (KBr) cm−1: 3438 (N-H),
1776, 1718 (C=O), 1588, 1505, 1484 (Ar), 1382 (N-O), 932 (OCH2O); ESR (1×10−5mol/L
in EtOH): go=2.0058, AN=14.9×10−4, ΔHo=2.66×10−4; MS (EI) (m/z): 706 [M+H]+; HRMS
(ESI)(m/z) for C38H45N2O11 [M+H]+: calc. 706.3023, found 706.3021.
4.3.5. Compound 12e—Yield 48%; m.p: 95–97 °C; IR (KBr) cm−: 3431 (N-H), 1774,
1718 (C=O), 1610, 1508, 1458 (Ar), 1364 (N-O), 932 (OCH2O); ESR (1×10−5mol/L in
EtOH): go=2.0057, AN=14.7×10−4, ΔHo=2.61×10−4; MS (EI) (m/z): 744 [M+H]+; HRMS
(ESI) (m/z) for C40H43N2O12 [M+H]+: calc. 744.2816, found 744.2815.
4.3.6. Compound 12f—Yield 64%; m.p: 105–107 °C; IR (KBr) cm−1: 3428 (N-H), 1775,
1719 (C=O), 1588, 1506, 1456 (Ar), 1384 (N-O), 931 (OCH2O); ESR (1×10−5mol/L in
EtOH): go=2.0057, AN=14.9×10−4, ΔHo=2.61×10−4; MS (EI) (m/z): 728 [M+H]+; HRMS
(ESI) (m/z) for C40H43N2O11 [M+H]+: calc. 728.2867, found 728.2864.
4.3.7. Compound 12g—Yield 62%; m.p: 119–121 °C; IR (KBr) cm−1: 3438 (N-H),
1776, 1719 (C=O), 1589, 1506, 1466 (Ar), 1383 (N-O), 930 (OCH2O); ESR (1×10−5 mol/L
in EtOH): go=2.0058, AN=14.9×10−4, ΔHo=2.65×10−4; MS (EI) (m/z): 705 [M+2H]+;
HRMS (ESI) (m/z) for C37H39N2O12 [M+Na]+: calc. 726.2503, found 726.2511.
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4.3.8. Compound 12h—Yield 59%; m.p: 110–112 °C; IR (KBr) cm−1: 3423 (N-H),
1774, 1718 (C=O), 1589, 1507, 1458 (Ar), 1363 (N-O), 931 (OCH2O); ESR (1×10−5 mol/L
in EtOH): go=2.0058, AN=14.7×10−4, ΔHo=2.61×10−4; MS (EI) (m/z): 758 [M+H]+; HRMS
(ESI) (m/z) for C40H41N2O13 [M+H]+: calc. 758.2609, found 758.2611.
4.3.9. Compound 12i—Yield 85%; m.p:110–112°C; IR (KBr) cm−1: 3436 (N-H), 1778,
1736 (C=O), 1588, 1506, 1465 (Ar), 1364 (N-O), 933 (OCH2O); ESR (1×10−5 mol/L in
EtOH): go=2.0057,AN=14.9×10−4,ΔHo=2.65×10−4; MS (EI) (m/z): 697 [M+2H]+; HRMS
(ESI) (m/z) for C37H47N2O11 [M+Na]+: calc. 718.3180, found 718.3185.
4.3.10. Compound 12j—Yield 76%; m.p: 106–108 °C; IR (KBr) cm−1: 3437 (N-H),
1778, 1718 (C=O), 1588, 1506, 1466 (Ar), 1362 (N-O), 934 (OCH2O); ESR (1×10−5 mol/L
in EtOH): go=2.0058, AN=14.7×10−4, ΔHo=2.67×10−4; MS (EI) (m/z): 694 [M+H]+; HRMS
(ESI) (m/z) for C37H45N2O11 [M+H]+: calc. 694.3023, found 694.3014.
4.4. General procedure for synthesis of 13a–l
Aldehyde/ketone (0.23 mmol), stable nitroxide radical acid (0.23 mmol), and 4β-
isocyanopodophyllotoxin (11) (0.18 mmol) were added sequentially to a solution of amine
(0.23 mmol) in MeOH (10 mL) at room temperature. The reaction mixture was heated at
reflux for 5 h. Upon completion of the reaction (TLC monitoring), the mixture cooled to
room temperature and solvent was evaporated. The crude reaction mixture was purified by
column chromatography (EtOAc/petroleum ether) to give the target product 13a–l.
4.4.1. Compound 13a—Yield 54%; m.p: 120–123 °C; IR (KBr) cm−1: 3448 (N-H), 1772
(C=O), 1592, 1507, 1465 (Ar), 1377 (N-O), 934 (OCH2O); ESR (1 × 10−5 mol/L in EtOH):
go=2.0058, AN=14.8×10−4, ΔHo=2.66×10−4; MS (EI) (m/z): 762 [M+2H]+; HRMS (ESI) (m/
z) for C40H54N3O10 [M+Na]+: calc.783.3809, found 783.3806.
4.4.2. Compound 13b—yield 47%; m.p: 103–105 °C; IR (KBr) cm−1: 3421 (N-H), 1775,
1718 (C=O), 1591, 1507, 1465 (Ar), 1358 (N-O), 931 (OCH2O); ESR (1 × 10−5 mol/L in
EtOH): go=2.0057, AN=14.8×10−4, ΔHo=2.65×10−4; MS (EI) (m/z): 755 [M+H]+; HRMS
(ESI) (m/z) for C42H48N3O10 [M+H]+: calc.755.3340, found 755.3343.
4.4.3. Compound 13c—Yield 42%; m.p: 157–159 °C; IR (KBr) cm−1: 3423 (N-H), 1777,
1735 (C=O), 1592, 1505, 1458 (Ar), 1368 (N-O), 932 (OCH2O); ESR (1 × 10−5 mol/L in
EtOH): go=2.0057, AN=14.8×10−4, ΔHo=2.65×10−4; MS (EI) (m/z): 805 [M+H]+; HRMS
(ESI) (m/z) for C46H50N3O10 [M+H]+: calc. 805.3496, found 805.3497.
4.4.4. Compound 13d—Yield 50%; m.p: 115–117°C; IR (KBr) cm−1: 3433 (N-H), 1772
(C=O), 1590, 1506, 1483 (Ar), 1370 (N-O), 934 (OCH2O); ESR (1×10−5 mol/L in EtOH):
go=2.0057, AN=14.9×10−4, ΔHo=2.65×10−4; MS (EI) (m/z): 708 [M+2H]+; HRMS (ESI) (m/
z) for C38H48N3O10 [M+K]+: calc. 745.3340, found 745.3342.
4.4.5. Compound 13e—Yied 42%; m.p: 115–116°C; IR (KBr) cm−1: 3429 (N-H), 1590,
1507, 1483 (Ar), 1363 (N-O), 934 (OCH2O); ESR (1×10−5 mol/L in EtOH): go=2.0058,
AN=14.7×10−4, ΔHo=2.61×10−4; MS (EI) (m/z): 72 1[M+H]+; HRMS (ESI) (m/z) for
C39H50N3O10 [M+H]+: calc. 721.3496, found 721.3493.
4.4.6. Compound 13f—Yield 68%; m.p: 86–88°C; IR (KBr) cm−1: 3434 (N-H), 1772
(C=O), 1592, 1507, 1466 (Ar), 1368 (N-O), 935 (OCH2O); ESR (1×10−5 mol/L in EtOH):
go=2.0057, AN=14.9×10−4, ΔHo=2.65×10−4; MS (EI) (m/z): 722 [M+2H]+; HRMS (ESI) (m/
z) for C39H50N3O10 [M+Na]+: calc.743.3496, found 743.3492.
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4.4.7. Compound 13g—Yield 84%; m.p: 147–149°C; IR (KBr) cm−1: 3426 (N-H), 1775
(C=O), 1507, 1458 (Ar), 1368 (N-O), 932 (OCH2O); ESR (1×10−5 mol/L in EtOH):
go=2.0057, AN=14.8×10−4, ΔHo=2.66×10−4; MS (EI) (m/z): 755 [M+H]+; HRMS (ESI) (m/
z) for C42H48N3O10 [M+H]+: calc. 755.3340, found 755.3342.
4.4.8. Compound 13h—Yield 60%; m.p: 95–96°C; IR (KBr) cm−1: 3392 (N-H), 1779,
1717 (C=O), 1609, 1508, 1451 (Ar), 1382 (N-O), 930 (OCH2O); ESR (1×10−5 mol/L in
EtOH): go=2.0058, AN=14.7×10−4, ΔHo=2.65×10−4; MS (EI) (m/z): 807 [M+Na]+; HRMS
(ESI) (m/z) for C43H50N3O11 [M+Na]+: calc. 807.3445, found 807.3443.
4.4.9. Compound 13i—Yield 76%; m.p: 106–109°C; IR (KBr) cm−1: 3426 (N-H), 1768
(C=O), 1591, 1506 (Ar), 1374 (N-O), 934 (OCH2O); ESR (1×10−5 mol/L in EtOH):
go=2.0058, AN=14.7×10−4, ΔHo=2.65×10−4; MS (EI) (m/z): 746 [M]+; HRMS (ESI) (m/z)
for C41H52N3O10 [M]+: calc.746.3653, found 746.3655.
4.4.10. Compound 13j—Yield 45%; m.p: 110–112 °C; IR (KBr) cm−1: 3447 (N-H), 1772
(C=O), 1590, 1507, 1466 (Ar), 1375 (N-O), 932 (OCH2O); ESR (1×10−5 mol/L in EtOH):
go=2.0058, AN=14.9×10−4, ΔHo=2.66×10−4; MS (EI) (m/z): 736 [M+2H]+; HRMS (ESI) (m/
z) for C40H52N3O10 [M+Na]+: calc.757.3653, found 757.3652.
4.4.11. Compound 13k—Yield 39%; m.p: 86–89°C; IR (KBr) cm−1: 3432 (N-H), 1772
(C=O), 1591, 1507, 1465 (Ar), 1378 (N-O), 935 (OCH2O); ESR (1×10−5mol/L in EtOH):
go=2.0057, AN=14.8×10−4, ΔHo=2.61×10−4; MS (EI) (m/z): 736 [M+2H]+; HRMS (ESI) (m/
z) for C40H52N3O10 [M+Na]+: calc. 757.3653, found 757.3652.
4.4.12. Compound 13l—Yield 46%; m.p: 92–94°C; IR (KBr) cm−1: 3356 (N-H), 1778
(C=O), 1585, 1451 (Ar), 1381 (N-O), 933 (OCH2O); ESR (1×10−5 mol/L in EtOH):
go=2.0057, AN=14.9×10−4, ΔHo=2.66×10−4; MS (EI) (m/z): 738 [M+2H]+; HRMS (ESI) (m/
z) for C40H54N3O10 [M+2H]+: calc.738.3809, found 738.3811.
4.5. Cytotoxicity assays
Cytotoxic activity was determined by the sulforhodamine B (SRB) colorimetric assay as
previously described [33]. In brief, the cells (3–5 × 103 cells/well) were seeded in 96-well
plates filled with RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS)
containing various concentrations of samples, and incubated for 72 h. At the end of the
exposure period, the attached cells were fixed with cold 50% trichloroacetic acid for 30 min
followed by staining with 0.04% SRB (Sigma Chemical Co.) for 30 min. The bound SRB
was solubilized in 10 mM Tris-base and the absorbance was measured at 515 nm on a
Microplate Reader ELx800 (Bio-Tek Instruments, Winooski, VT) with a Gen5 software. All
results were representative of three or more experiments.
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New spin-labeled podophyllotoxin analogs were prepared and tested for cytotoxicity.
The synthesis used an isocyanide multicomponent coupling reaction.
Potent cytotoxicity was found against A-549, DU-145, KB and KBvin cancer cell lines.
Two compounds (12e, 12h) showed superior potency to etoposide.
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Structures of podophyllotoxin derivatives.
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Synthesis of target compounds 12a–j via the Passerini reaction.
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Synthesis of target compounds 13a–l via the Ugi reaction.
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Table 1
In vitro cytotoxicity of compounds 12a–j and 13a–c against four human tumor cell lines a
Compd
IC50 (µM)
A549 DU145 KB KBvin
12a 2.38±0.27 2.39±0.26 2.32±0.12 2.55±0.55
12b >20 >20 >20 >20
12c 8.86±0.43 7.07±0.44 7.12±0.45 8.88±0.37
12d 9.52±0.82 8.74±0.77 9.24±1.57 13.68±1.96
12e 0.75±0.02 0.63±0.09 0.60±0.02 0.73±0.06
12f 7.68±0.37 6.82±0.16 6.53±0.06 7.71±0.19
12g 7.38±0.04 6.55±0.12 7.12±0.22 7.35±0.36
12h 1.46±0.17 1.37±0.08 1.12±0.13 2.03±0.38
12i 8.82±0.26 7.13±0.07 6.58±0.14 7.96±0.14
12j 9.05±0.26 7.27±0.05 6.88±0.24 8.35±0.06
13a 8.98 ± 1.21 10.95 ± 1.20 9.35± 2.01 8.83 ± 1.33
13b 8.40 ± 0.304 9.78± 2.20 8.49± 0.72 7.47 ± 1.15
13c 6.10± 0.192 6.08 ± 0.138 5.94 ± 0.37 6.45± 0.396
2 2.58±0.252 2.03±0.121 3.88±0.199 >20
a
The results are average of three independent experiments. Compounds 13d–13l did not show significant inhibition (IC50 > 20 µM).
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